Credit Suisse’s Lucid Diagnostics LUCD Stock Holding History

Credit Suisse’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3	Closed	–	–	4174
2022 Q2	$0	Buy	+3	New	+$7	﹤0.01%	4147

Other funds holding LUCD

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Credit Suisse's LUCD Position: Q3 2022 in Review

Credit Suisse sold out of Lucid Diagnostics (LUCD) in Q3 2022, closing a stake of 3 shares.

Credit Suisse first reported a position in LUCD in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 23 funds tracked by Wall St. Rank hold LUCD as of Q3 2022.

Credit Suisse reported no remaining Lucid Diagnostics position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 3 Lucid Diagnostics shares in Q3 2022.
Credit Suisse first reported a position in Lucid Diagnostics in Q2 2022 and held it in 1 quarter.
Credit Suisse's Lucid Diagnostics position peaked at $0 in Q2 2022.
23 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.